German life science company Sartorius will merge Slovenian purification specialist BIA Separations with Sartorius Stedim Biotech, in a deal worth €360m ($423m).
Sartorius launches a new vessel for its ambr 250 modular bioreactor system to potentially accelerate cell and gene therapy process development and scale up into cGMP single-use bioreactors and bags.
Supply chain issues stemming from an FDA warning letter at a facility run by its partner Lonza have dampened Sartorius Stedim Biotech’s first half 2017 results.
While in its early stages, the three-dimensional printing device enclosed in a disposable system could ensure sterile manufacturing of miniaturised organ models or even bioprocessing equipment parts, says Sartorius.
Sartorius has launched a cell harvesting technology, the first to incorporate diatomaceous earth filtration more commonly associated with the brewing industry.
Close relationships between vendors and biomanufacturers are critical according to Sartorius, which was been awarded an accolade for the design of WuXi AppTec’s biologics production facility in China.
Sartorius has confirmed it will make the Ambr microreactor technology it acquired with Tap Biosystems compatible with its own downstream processing systems.
Sartorius Stedim Biotech (SSB) and Bayer Technology Services (BTS) have signed an exclusive cooperation agreement for the manufacture and marketing of UVivatec products.
